• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].

作者信息

Walter-Sack I, Gröbner W, Zöllner N

出版信息

Arzneimittelforschung. 1979;29(5):839-42.

PMID:582985
Abstract

Oxipurinol plasma levels and plasma elimination half-life were investigated in five healthy volunteers after oral administration of 300 mg allopurinol in customary (A 300) and in slow-release preparation (A ret) in a double blind cross-over study. After a single oral dose of 300 mg allopurinol in customary preparation maximum oxipurinol plasma levels were 5.24 microgram/ml. After allopurinol in slow-release preparation maximum oxipurinol levels were 2.22 microgram/ml. 24-h oxipurinol plasma levels were 3.78 microgram/ml after A 300 and 2.08 microgram/ml after A ret, respectively. Chronic oral administration of a daily dose of 300 mg allopurinol resulted in accumulation of oxipurinol until day 8. 24-h steady-state levels of oxipurinol were found to be 9.98 microgram/ml after A 300 and 7.14 microgram/ml after A ret. All oxipurinol plasma levels on A 300 exceeded those on A ret. The time course of oxipurinol plasma levels after a single oral dose of allopurinol suggests that oxipurinol elimination from plasma follows an exponential function (first-order elimination). Plasma elimination half-life of oxipurinol was 42.65 h after administration of A 300 and 49.91 h after administration of A ret. The difference between the elimination half-lives is statistically not significant.

摘要

相似文献

1
[Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
Arzneimittelforschung. 1979;29(5):839-42.
2
[Pharmacokinetic studies on plasma elimination half-life of oxipurinol (author's transl)].
Arzneimittelforschung. 1982;32(1):76-9.
3
[The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Arzneimittelforschung. 1985;35(7):1093-6.
4
[Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Arzneimittelforschung. 1986 Jun;36(6):988-93.
5
[A new and quick method for determination of allopurinol and oxipurinol in serum (author's transl)].血清中别嘌呤醇和氧嘌呤醇测定的一种新的快速方法(作者译)
Arzneimittelforschung. 1980;30(11):1855-7.
6
Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol.氧嘌呤醇钠对高尿酸血症患者的降尿酸作用——与别嘌醇的治疗等效性。
J Rheumatol. 1996 Mar;23(3):498-501.
7
Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.长期口服给药后别嘌醇和氧嘌呤醇的动力学。与苯溴马隆的相互作用。
Eur J Clin Pharmacol. 1986;31(1):53-8. doi: 10.1007/BF00870986.
8
[The use of allopurinol in long-term treatments for optimal effect].[使用别嘌醇进行长期治疗以达到最佳效果]
Fortschr Med. 1980 Mar 13;98(10):(373-6).
9
Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.服用别嘌醇的志愿者血浆氧嘌呤醇浓度与黄嘌呤氧化酶活性之间的关系。
Br J Clin Pharmacol. 1988 Oct;26(4):429-34. doi: 10.1111/j.1365-2125.1988.tb03402.x.
10
Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.氧嘌呤醇的处置及降尿酸作用:健康个体中不同氧嘌呤醇制剂与别嘌醇的比较
Eur J Clin Pharmacol. 1995;49(3):215-20. doi: 10.1007/BF00192382.

引用本文的文献

1
Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?
Clin Investig. 1993 Mar;71(3):240-6. doi: 10.1007/BF00180109.
2
Allopurinol and oxypurinol in human breast milk.
Clin Investig. 1993 Feb;71(2):161-4. doi: 10.1007/BF00179999.
3
The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.苯溴马隆对痛风患者别嘌醇/氧嘌呤醇动力学的影响。
Eur J Clin Pharmacol. 1993;44(1):69-72. doi: 10.1007/BF00315283.
4
Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.在正常受试者中长期口服别嘌醇和氢氯噻嗪期间二者的相互作用。I. 尿酸动力学
Clin Investig. 1994 Dec;72(12):1071-5. doi: 10.1007/BF00577758.
5
Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.
Eur J Clin Pharmacol. 1982;22(1):77-84. doi: 10.1007/BF00606429.
6
Clinical pharmacokinetics of allopurinol.别嘌醇的临床药代动力学。
Clin Pharmacokinet. 1986 Sep-Oct;11(5):343-53. doi: 10.2165/00003088-198611050-00001.
7
The influence of nutrition on the systemic availability of drugs. Part II: Drug metabolism and renal excretion.营养对药物全身可利用性的影响。第二部分:药物代谢与肾排泄。
Klin Wochenschr. 1987 Nov 2;65(21):1062-72. doi: 10.1007/BF01726326.
8
Alteration of oral carbohydrate tolerance during administration of a fiber-free formula diet.
Klin Wochenschr. 1987 Feb 2;65(3):121-8. doi: 10.1007/BF01728603.